Document is current
Any future updates will be listed below
-
Authors
Ralli, G. P.
Carter, R. D.
McGowan, D. R.
Cheng, W.-C.
Liu, D.
Teoh, E. J.
Patel, N.
Gleeson, F.
Harris, A. L.
Lord, S. R.
Buffa, F. M.
Fenwick, J. D.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01266486 at ClinicalTrials.govDocuments that mention this clinical trial
Radiogenomic analysis of primary breast cancer reveals [18F]-fluorodeoxglucose dynamic flux-constants are positively associated with immune pathways and outperform static uptake measures in associating with glucose metabolism
https://doi.org/10.1186/s13058-022-01529-9
-
Funding
Funding for this research was provided by:
Cancer Research UK (C5255/A16466, C5255/A16466, C5255/A16466, C5255/A16466, C5255/A16466, C5255/A16466, C5255/A16466)
Biotechnology and Biological Sciences Research Council (BB/M01224/1)
Breast Cancer Research Foundation (BCRF-18-064, BCRF-18-064)
- License Information
-
More Information
Article History
Received: 19 January 2022
Accepted: 11 May 2022
First Online: 17 May 2022
Declarations
:
: The metformin study was prospectively approved by NHS Oxfordshire Research Ethics Committee A and registered with the ClinicalTrials.gov identifier NCT01266486. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments. Informed consent was obtained from all individual participants included within the study.
: Additional informed consent was obtained from all individual participants for publication of FDG-PET images.
: The authors declare that they have no competing interests.
